Literature DB >> 11169919

The human interferon alpha species and receptors.

S Pestka1.   

Abstract

Interferon (IFN) was approved by the U.S. Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for development of many other cytokines and growth factors. Nevertheless, we have just touched the surface of understanding the multitude of human IFNs. This paper reviews the history of the purification of human leukocyte IFN and key aspects of our current state of knowledge of human interferon alpha genes, proteins, and receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11169919     DOI: 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  29 in total

1.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

2.  The Tumor Suppressive Effects of HPP1 Are Mediated Through JAK-STAT-Interferon Signaling Pathways.

Authors:  Jonathan M Hernandez; Abul Elahi; Whalen Clark; Leigh Ann Humphries; Jian Wang; Alex Achille; Ed Seto; David Shibata
Journal:  DNA Cell Biol       Date:  2015-05-19       Impact factor: 3.311

Review 3.  Structure of interleukin-10/interleukin-10R1 complex: a paradigm for class 2 cytokine activation.

Authors:  Mark R Walter
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Innate STAT1-dependent genomic response of neurons to the antiviral cytokine alpha interferon.

Authors:  Jianping Wang; Iain L Campbell
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Identification of genes involved in the host response to enterovirus 71 infection.

Authors:  Shin-Ru Shih; Victor Stollar; Jing-Yi Lin; Shih-Cheng Chang; Guang-Wu Chen; Mei-Ling Li
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

6.  SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.

Authors:  Bret Poat; Sidhartha Hazari; Partha K Chandra; Feyza Gunduz; Luis A Balart; Xavier Alvarez; Srikanta Dash
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

Review 7.  Inteferons pen the JAK-STAT pathway.

Authors:  Christian Schindler; Courtney Plumlee
Journal:  Semin Cell Dev Biol       Date:  2008-08-26       Impact factor: 7.727

8.  Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon.

Authors:  Luigi E Adinolfi; Emanuele Durante-Mangoni; Marta Salzillo; Aldo Marrone; Marie-Francoise Tripodi; Luciano Restivo; Antonietta Merola; Rosa Zampino; Giuseppe Ruggiero
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

9.  Long-term pegylated interferon-alpha and its potential in the treatment of melanoma.

Authors:  Reinhard Dummer; Joanna Mangana
Journal:  Biologics       Date:  2009-07-13

10.  Signaling pathways involved in liver injury and regeneration in rabbit hemorrhagic disease, an animal model of virally-induced fulminant hepatic failure.

Authors:  Rodrigo García-Lastra; Beatriz San-Miguel; Irene Crespo; Francisco Jorquera; Marcelino Alvarez; Javier González-Gallego; María J Tuñón
Journal:  Vet Res       Date:  2009-09-03       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.